Company Midatech Pharma PLC Nasdaq

Equities

US59564R1041

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Group companies

Sector

Sector Bio Therapeutic Drugs

Inactive Instrument

Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.

USD in Million	2022	Weight	2023	Weight	Delta
Pipeline Research and Development 100.0 %	1	100.0 %	0	100.0 %	-44.99%

USD in Million	2022	Weight	2023	Weight	Delta
Belgium 100.0 %	1	100.0 %	0	100.0 %	-44.99%

Managers	Title	Age	Since
Stephen Stamp CEO	Chief Executive Officer	62	09/19/09
Dan Palmer CTO	Chief Tech/Sci/R&D Officer	-	-
Dmitry Zamoryakhin CTO	Chief Tech/Sci/R&D Officer	44	11/21/11
Steve Ellul PRN	Corporate Officer/Principal	-	01/22/01
Fiona Sharp AUD	Comptroller/Controller/Auditor	-	-

Members of the board	Title	Age	Since
Stephen Parker CHM	Chairman	65	20/22/20
Sijmen de Vries BRD	Director/Board Member	65	13/14/13
Stephen Stamp CEO	Chief Executive Officer	62	09/19/09
Simon Turton BRD	Director/Board Member	56	02/14/02
Ann Merchant BRD	Director/Board Member	59	31/12

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	400	2,973,944,305	2,619,516 ( 0.0881 %)	0	0.0881 %

Name	Equities	%	Valuation
Mercer Street Global Opportunity Fund LLC 64.64 %	62,496,800	64.64 %	625 $
Michael Bigger 4.608 %	4,455,260	4.608 %	45 $
L1 Global Manager Pty Ltd. 0.5603 %	541,700	0.5603 %	5 $
Ionic Ventures LLC 0.1402 %	135,532	0.1402 %	1 $
Stephen Stamp 0.0271 %	26,188	0.0271 %	0 $
Simon Turton 0.002861 %	2,766	0.002861 %	0 $
Sijmen de Vries 0.001367 %	1,322	0.001367 %	0 $
Walleye Capital LLC 0.000000 %	0	0.000000 %	- $
Merrill Lynch International (Investment Management) 0.000000 %	0	0.000000 %	- $
S.H.N. Financial Investments Ltd. 0.000000 %	0	0.000000 %	- $

Name	Equities	%	Valuation
Armistice Capital LLC 9.516 %	24,951	9.516 %	24 053 $
GAMMA Investing LLC 4.234 %	11,101	4.234 %	10 701 $
Bank of America, NA (Charlotte, North Carolina) 1.997 %	5,236	1.997 %	5 048 $
Cavalry Fund I Management LLC 1.056 %	2,768	1.056 %	2 668 $
UBS Securities LLC 0.9298 %	2,438	0.9298 %	2 350 $
RhumbLine Advisers LP 0.1899 %	498	0.1899 %	480 $
Morgan Stanley Capital Services LLC 0.006102 %	16	0.006102 %	15 $

Biodexa Pharmaceuticals Plc

1 Caspian Point Caspian Way

CF10 4DQ, Cardiff

+44 29 2048 0180

http://www.midatechpharma.com

Name	Category and Sector
Midatech Pharma España SL Midatech Pharma España SL Pharmaceuticals: MajorHealth Technology Part of Biodexa Pharmaceuticals Plc, Midatech Pharma España SL is a pharmaceutical company located in Spain. The Spanish company operates in the field of oncology and other areas.	Pharmaceuticals: Major

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+18.15%	124B
REGENERON PHARMACEUTICALS, INC.	+18.02%	112B
ARGENX SE	+5.07%	22.94B
BIONTECH SE	-12.75%	22.22B
BEIGENE, LTD.	-9.86%	17.02B
GENMAB A/S	-14.97%	16.88B
WUXI APPTEC CO., LTD.	-39.94%	16.87B
NEUROCRINE BIOSCIENCES, INC.	+2.80%	13.63B
SAREPTA THERAPEUTICS, INC.	+27.39%	11.61B

Bio Therapeutic Drugs